ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Low-dose RSV mRNA vaccine

Also written as “High-dose RSV mRNA vaccine”.

Its studies are led by Sinovac Biotech.

Furthest: phase 1, since Feb 11, 20261 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech11 open or runningphase 1since Feb 11, 2026Feb 11, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2026First study: phase 1 study in RSVFirst studyNCT07418229 · 60 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Low-dose RSV mRNA vaccine”name, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07418229RSV · China1Not yet recruitingJun 30, 202660

How it is read

Names in the registry

  • “Low-dose RSV mRNA vaccine”, 1 entry
  • “High-dose RSV mRNA vaccine”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.